Clarametyx Biosciences

Clarametyx Biosciences company information, Employees & Contact Information

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

Company Details

Employees
22
Founded
-
Address
1275 Kinnear Rd, Columbus,ohio 43212,united States
Phone
614.686.2689
Email
in****@****tyx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Columbus, Ohio
Looking for a particular Clarametyx Biosciences employee's phone or email?

Clarametyx Biosciences Questions

News

Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress - Business Wire

Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress Business Wire

Clarametyx completes enrolment in cystic fibrosis trial - Clinical Trials Arena

Clarametyx completes enrolment in cystic fibrosis trial Clinical Trials Arena

Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic Fibrosis - Business Wire

Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic Fibrosis Business Wire

Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2A Study Evaluating CMTX-101 for Infections Associated With Cystic Fibrosis - BioSpace

Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2A Study Evaluating CMTX-101 for Infections Associated With Cystic Fibrosis BioSpace

Clarametyx Biosciences Announces FDA Grant of Fast Track and Qualified Infectious Disease Product Designations for CMTX-101 - Yahoo Finance

Clarametyx Biosciences Announces FDA Grant of Fast Track and Qualified Infectious Disease Product Designations for CMTX-101 Yahoo Finance

Nationwide Children's spinoff targeting antibiotic resistance starts developing vaccine - The Business Journals

Nationwide Children's spinoff targeting antibiotic resistance starts developing vaccine The Business Journals

Clarametyx to advance trial of CMTX-101 with DMC approval - Clinical Trials Arena

Clarametyx to advance trial of CMTX-101 with DMC approval Clinical Trials Arena

FDA fast-tracks antibody treatment targeting bacterial biofilms - CIDRAP

FDA fast-tracks antibody treatment targeting bacterial biofilms CIDRAP

Innovators in Healthcare and Life Sciences Awards: Clarametyx Biosciences - Columbus Business First - The Business Journals

Innovators in Healthcare and Life Sciences Awards: Clarametyx Biosciences - Columbus Business First The Business Journals

FDA Fast Tracks Antibody Therapy for Pulmonary Infections Including Cystic Fibrosis - Contagion Live

FDA Fast Tracks Antibody Therapy for Pulmonary Infections Including Cystic Fibrosis Contagion Live

CF trial completes enrollment, nears top-line results for lung infections - Cystic Fibrosis News Today

CF trial completes enrollment, nears top-line results for lung infections Cystic Fibrosis News Today

Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund - Business Wire

Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund Business Wire

Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis Patients - Contagion Live

Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis Patients Contagion Live

FDA puts CMTX-101 on fast track for treating CF lung infections - Cystic Fibrosis News Today

FDA puts CMTX-101 on fast track for treating CF lung infections Cystic Fibrosis News Today

Clarametyx Biosciences Awarded a Multi-Phased Agreement With CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial Infections - Business Wire

Clarametyx Biosciences Awarded a Multi-Phased Agreement With CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial Infections Business Wire

Clarametyx launches Phase Ib/IIa cystic fibrosis therapy trial - Clinical Trials Arena

Clarametyx launches Phase Ib/IIa cystic fibrosis therapy trial Clinical Trials Arena

Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections - Business Wire

Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections Business Wire

CARB-X funds development of anti-biofilm vaccine - CIDRAP

CARB-X funds development of anti-biofilm vaccine CIDRAP

Charlotte Rogers Obituary July 10, 2025 - newcomerdayton.com

Charlotte Rogers Obituary July 10, 2025 newcomerdayton.com

FDA accepts IND application for Clarametyx antibody therapy CMTX-101 - Drug Target Review

FDA accepts IND application for Clarametyx antibody therapy CMTX-101 Drug Target Review

Top Clarametyx Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant